Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix
Article 1999 en
Authors
CP
Christos Papadimitriou
KS
K. Sarris
LM
Lia A. Moulopoulos
Abstract
1 min read
The combination of paclitaxel with cisplatin seems relatively well tolerated and moderately active in patients with metastatic or recurrent cervical cancer. The significant incidence of neurotoxicity is of concern, and alternative methods of administration of the two agents could be evaluated. Then, further study of this combination, alone or with the addition of other active agents, is warranted.
Jim Janinis, George P. Stathopoulos, Paul Nikolaidis, Haralabos P. Kalofonos, Anna Kalogera‐Fountzila, E. Samantas, Gerasimos Aravantinos, Athanassios Anagnostopoulos, Christos Tolis, Thomas Makatsoris, S. Rigatos, Dimitrios Bafaloukos, Meletios A Dimopoulos, John Daniilidis, George Fountzilas
David Barnes, Peter H. Dutton, Øyvind S. Bruland, Hans Gelderblom, Ade Faleti, Claudia Bühnemann, Annemiek van Maldegem, Hannah Johnson, Lisa Poulton, Sharon Love, Gesa Tiemeier, Els van Beelen, Karin H. Herbschleb, Caroline Haddon, Lucinda Billingham, Kevin M. Bradley, Stefano Ferrari, Emanuela Palmerini, Piero Picci, Uta Dirksen, Sandra J. Strauss, Pancras C.W. Hogendoorn,
Discussion(0)
No comments yet. Be the first to comment.